- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vicore Pharma Holding AB (VICOR)
Vicore Pharma Holding AB stock price live, this page displays ST VICOR stock exchange data. View the VICOR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Vicore Pharma Holding AB real time stock price chart below.
What Is the Vicore Pharma Holding AB Stock Price Today?
The Vicore Pharma Holding AB stock price today is 9.410.
What Is the Stock Symbol for Vicore Pharma Holding AB?
The stock symbol for Vicore Pharma Holding AB is "VICOR."
What Stock Exchange Does Vicore Pharma Holding AB Trade On?
Vicore Pharma Holding AB is listed and trades on the Stockholm stock exchange.
Is Vicore Pharma Holding AB a Good Stock to Buy?
Determining whether Vicore Pharma Holding AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VICOR quote. (ISIN: SE0007577895)
What Is the Vicore Pharma Holding AB Stock Price Today?
The Vicore Pharma Holding AB stock price today is 9.410.
What Is the Stock Symbol for Vicore Pharma Holding AB?
The stock symbol for Vicore Pharma Holding AB is "VICOR."
What Stock Exchange Does Vicore Pharma Holding AB Trade On?
Vicore Pharma Holding AB is listed and trades on the Stockholm stock exchange.
Is Vicore Pharma Holding AB a Good Stock to Buy?
Determining whether Vicore Pharma Holding AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VICOR quote. (ISIN: SE0007577895)
9.410
-0.170(-1.77%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.390
9.620
52 wk Range
8.620
18.240
VICOR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.3909.620
52 wk Range
8.62018.240
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VICOR Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
26.917
Upside
+186.04%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 26.917
(+186.04% Upside)
Earnings
Latest Release
Aug 21, 2026
EPS / Forecast
-0.51 / -0.51
Revenue / Forecast
2.2M / 477K
Compare VICOR to Peers and Sector
Metrics to compare | VICOR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVICORPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.4x | −3.0x | −0.3x | |
PEG Ratio | 2.83 | −0.87 | 0.00 | |
Price/Book | 3.2x | 2.5x | 2.6x | |
Price / LTM Sales | 675.3x | 23.7x | 3.0x | |
Upside (Analyst Target) | 181.0% | 162.4% | 56.4% | |
Fair Value Upside | Unlock | 19.8% | 7.2% | Unlock |
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Vicore Pharma Holding AB (VICOR) Stock Price Today?
The Vicore Pharma Holding AB stock price today is 9.410 SEK.
What Stock Exchange Does Vicore Pharma Holding AB Trade On?
Vicore Pharma Holding AB is listed and trades on the Stockholm Stock Exchange.
What Is the Stock Symbol for Vicore Pharma Holding AB?
The stock symbol for Vicore Pharma Holding AB is "VICOR."
What Is the Vicore Pharma Holding AB Market Cap?
As of today, Vicore Pharma Holding AB market cap is 2.700B SEK.
What Is Vicore Pharma Holding AB's Earnings Per Share (TTM)?
The Vicore Pharma Holding AB EPS (TTM) is -1.906.
When Is the Next Vicore Pharma Holding AB Earnings Date?
Vicore Pharma Holding AB will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is VICOR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Vicore Pharma Holding AB Stock Split?
Vicore Pharma Holding AB has split 1 times.
How Many Employees Does Vicore Pharma Holding AB Have?
Vicore Pharma Holding AB has 46 employees.
What is the current trading status of Vicore Pharma Holding AB (VICOR)?
As of Oct 01, 2026, Vicore Pharma Holding AB (VICOR) is trading at a price of 9.410 SEK, with a previous close of 9.410 SEK. The stock has fluctuated within a day range of 9.390 SEK to 9.620 SEK, while its 52-week range spans from 8.620 SEK to 18.240 SEK.
What Is Vicore Pharma Holding AB (VICOR) Price Target According to Analysts?
The average 12-month price target for Vicore Pharma Holding AB is 26.917 SEK, with a high estimate of 38 SEK and a low estimate of 15 SEK. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +186.04% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.